RARA and leukemia: We previously demonstrated that promyelocytic leukemia/retinoic acid receptor alpha (PML/RARa) hybrid protein inhibits Nrf2 function, impedes its transfer to the nucleus, and enhances its degradation in the cytoplasm, but mRNA levels are similar to those found in other AML subtypes.